Literature DB >> 6583450

Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors.

P M Capone, L D Papsidero, T M Chu.   

Abstract

The relationship between the level of cell surface antigen expression and solid tumor immunotherapy with monoclonal antibody (MoAb) was evaluated. Two MoAb's that were shown effective in the passive therapy of breast carcinomas of human origin, established and growing in female Swiss nude mice, were used for these studies. Several groups of tumors were produced from cell cultures of different passages; each cell culture possessed a distinct target antigen level. Results from immunotherapy experiments demonstrated that the amount of tumor reduction response after MoAb therapy was proportional to the antigen density at the cell surface. Analysis of these data indicated a theoretical improbability of a single MoAb treatment being able to completely eradicate solid tumors and may necessitate the use of multiple MoAb's to circumvent this problem.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6583450

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  22 in total

Review 1.  Analysis on the current status of targeted drug delivery to tumors.

Authors:  Il Keun Kwon; Sang Cheon Lee; Bumsoo Han; Kinam Park
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

2.  Heterogeneous expression of a murine B16 melanoma-associated antigen correlates with cell cycle.

Authors:  S P Leong; P D Noguchi; R E Cunningham; T Takami; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Targeted drug delivery to tumors: myths, reality and possibility.

Authors:  You Han Bae; Kinam Park
Journal:  J Control Release       Date:  2011-06-06       Impact factor: 9.776

Review 4.  Antibody-directed enzyme prodrug therapy.

Authors:  K D Bagshawe
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

Review 5.  From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

Authors:  Ignazio Caruana; Iulia Diaconu; Gianpietro Dotti
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

6.  Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer.

Authors:  W Schmiegel; J Schmielau; D Henne-Bruns; H Juhl; C Roeder; P Buggisch; A Onur; B Kremer; H Kalthoff; E V Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Authors:  Chien-Tsun Kuan; Kenji Wakiya; James E Herndon; Eric S Lipp; Charles N Pegram; Gregory J Riggins; Ahmed Rasheed; Scott E Szafranski; Roger E McLendon; Carol J Wikstrand; Darell D Bigner
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

8.  Monoclonal antibodies against antigens on breast cancer cells.

Authors:  C Stähli; B Takacs; V Miggiano; T Staehelin; H Carmann
Journal:  Experientia       Date:  1985-11-15

9.  Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody.

Authors:  P M Capone; N Kadohama; T M Chu
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Growth inhibition of experimental glioma grafts by monoclonal antibody treatment.

Authors:  D Stavrou; W Mellert; U Mellert; E Keiditsch; K Bise; P Mehraein
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.